These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29423677)

  • 1. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
    Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
    Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
    Sun W; Li J
    Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.
    Solomon BM; Jatoi A
    J Palliat Med; 2011 Feb; 14(2):153-6. PubMed ID: 21226620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
    Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
    Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rash from EGFR inhibitors: opportunities and challenges for palliation.
    Solomon BM; Jatoi A
    Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
    Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
    Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
    Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
    Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
    Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
    Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
    J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin problems and EGFR-tyrosine kinase inhibitor.
    Kozuki T
    Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
    Rhee J; Oishi K; Garey J; Kim E
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
    Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
    Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
    Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
    Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
    Vaubel J; Livingstone E; Schadendorf D; Zimmer L
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.